Allurion Technologies Inc. (ALUR) 股票分析

公司概述

Allurion Technologies Inc. operates within the healthcare sector, specifically targeting the medical devices industry by providing a specialized solution to end obesity through a proprietary weight loss platform designed for individuals who are overweight. The company's core business revolves around the Allurion Program, which features a swallowable and procedure-less intragastric balloon intended for weight loss, alongside access to artificial intelligence-powered remote patient monitoring services. In terms of operational scale, Allurion Technologies Inc. currently employs 38 staff members and holds a market capitalization of $12.00 million, with annual trailing twelve-month revenue reaching $15.23 million. These valuation and revenue figures indicate that the company operates as a small-cap entity with a modest revenue base relative to its valuation, suggesting a company that is still in a developmental phase where revenue generation is not yet sufficient to cover its substantial operating expenses and debt obligations.

财务健康

The company reported a revenue of $15.23 million over the trailing twelve months, yet this revenue generated a net income of -$28,755,000 and an EBITDA of -$29,174,000, revealing a significant gap where operating costs and expenses drastically exceed the revenue generated. The free cash flow stands at -$16,837,124, indicating that the company is currently burning cash rapidly, which severely limits its financial flexibility and ability to fund operations or investments without external financing. Regarding profitability margins, the gross margin is 62.8%, suggesting that the core product has a healthy markup on sales before operating expenses; however, the operating margin is -174.2% and the profit margin is -188.8%, which indicates that general and administrative costs, research and development, and other overhead expenses are disproportionately high compared to the revenue stream. On the balance sheet, the company holds $5.41 million in cash but carries $76.74 million in debt, creating a situation where liabilities far outweigh liquid assets, and the debt-to-equity ratio is listed as N/A due to the lack of positive equity. The current ratio is 0.33, which indicates a severe short-term liquidity constraint where current liabilities exceed current assets by more than threefold, signaling a high risk of solvency issues if cash inflows do not improve immediately. Furthermore, the return on equity is N/A and the return on assets is -77.6%, revealing that management is not generating positive returns on the capital invested by shareholders or the assets employed, reflecting the intense financial strain on the organization.

估值评估

The trailing twelve-month P/E ratio is N/A because the company has no earnings, while the forward P/E is -0.65, implying that the market expects earnings to remain negative or that the valuation metric is not applicable in a traditional sense due to the lack of profitability. The price-to-book ratio is -0.13, which indicates that the stock is trading at a negative multiple relative to its book value, a common occurrence for companies with substantial debt and negative shareholders' equity where the market price does not reflect any underlying tangible asset premium. Alternative valuation metrics show a price-to-sales ratio of 0.79 and an EV/EBITDA of -2.86, suggesting that the market is pricing the company based on its revenue potential rather than earnings power, though the negative EV/EBITDA highlights the heavy debt load relative to earnings. The stock has seen significant volatility with a 52-week high of $3.42 and a 52-week low of $0.23; assuming a current trading price near the lower end of the range, the stock is trading significantly below its 52-week high, reflecting investor caution regarding its financial trajectory. The beta value is -0.25, which is an anomalous negative figure indicating that the stock's price movement has historically moved inversely to the broader market, though such a negative beta is rare and suggests unique trading characteristics or data anomalies specific to this micro-cap.

Growth & Income

The company experienced a revenue growth rate of -35.4% year-over-year, while earnings growth is N/A due to the absence of positive net income, indicating that the company is actively contracting in revenue terms rather than expanding its market share or sales volume. For dividend payers, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. For non-dividend payers, Allurion Technologies Inc. reinvests its limited resources into growth initiatives, product development, or debt management rather than paying cash dividends to investors. The overall growth and income profile is characterized by negative revenue momentum, a complete lack of dividend income, and a reliance on external capital markets to sustain operations while attempting to reverse the steep decline in sales.